Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has received an average recommendation of “Hold” from the seven research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $16.33.

Several equities research analysts recently commented on the company. BidaskClub downgraded Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 27th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Foamix Pharmaceuticals in a report on Monday, July 16th. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 8th. Cowen set a $30.00 price objective on Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Finally, ValuEngine downgraded Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 4th.

NASDAQ FOMX traded down $0.16 during trading hours on Monday, hitting $4.42. The company’s stock had a trading volume of 419,330 shares, compared to its average volume of 759,098. Foamix Pharmaceuticals has a 12 month low of $4.12 and a 12 month high of $7.60. The company has a market capitalization of $240.97 million, a price-to-earnings ratio of -2.51 and a beta of 2.10.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings data on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Foamix Pharmaceuticals had a negative return on equity of 148.15% and a negative net margin of 2,049.92%. The business had revenue of $0.87 million during the quarter, compared to the consensus estimate of $1.10 million. On average, equities research analysts anticipate that Foamix Pharmaceuticals will post -1.64 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC grew its stake in shares of Foamix Pharmaceuticals by 223.2% during the 2nd quarter. Orbimed Advisors LLC now owns 4,040,000 shares of the specialty pharmaceutical company’s stock valued at $20,240,000 after purchasing an additional 2,790,000 shares during the period. AXA grew its stake in shares of Foamix Pharmaceuticals by 43.8% during the 3rd quarter. AXA now owns 1,369,341 shares of the specialty pharmaceutical company’s stock valued at $7,846,000 after purchasing an additional 416,787 shares during the period. Millennium Management LLC grew its stake in shares of Foamix Pharmaceuticals by 2.6% during the 1st quarter. Millennium Management LLC now owns 763,296 shares of the specialty pharmaceutical company’s stock valued at $3,916,000 after purchasing an additional 19,628 shares during the period. Handelsbanken Fonder AB grew its stake in shares of Foamix Pharmaceuticals by 64.1% during the 3rd quarter. Handelsbanken Fonder AB now owns 640,000 shares of the specialty pharmaceutical company’s stock valued at $3,667,000 after purchasing an additional 250,000 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Foamix Pharmaceuticals by 26.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 636,127 shares of the specialty pharmaceutical company’s stock valued at $3,645,000 after purchasing an additional 134,676 shares during the period. Institutional investors and hedge funds own 47.01% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Further Reading: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.